

**ENTERED**

February 06, 2024

Nathan Ochsner, Clerk

**IN THE UNITED STATES BANKRUPTCY COURT  
FOR THE SOUTHERN DISTRICT OF TEXAS  
HOUSTON DIVISION**

In re:

Chapter 11

SORRENTO THERAPEUTICS, INC., *et al.*<sup>1</sup>

Case No. 23-90085 (CML)

Debtors.

(Jointly Administered)


**Re: Docket No. 1644****ORDER GRANTING THIRD INTERIM FEE APPLICATION  
OF M3 ADVISORY PARTNERS, LP FOR COMPENSATION FOR SERVICES  
RENDERED AND FOR REIMBURSEMENT OF EXPENSES AS CHIEF  
RESTRUCTURING OFFICER AND FINANCIAL ADVISOR TO THE DEBTORS  
FOR THE PERIOD FROM SEPTEMBER 1, 2023 THROUGH NOVEMBER 30, 2023**

The Court has considered the Third Interim Fee Application of M3 Advisory Partners, LP for Compensation for Services Rendered and for Reimbursement of Expenses as Chief Restructuring Officer and Financial Advisor to the Debtors for the Period from September 1, 2023 Through November 30, 2023 (the "Application"), filed by M3 Advisory Partners, LP (the "Applicant"). The Court orders:

1. The Applicant is allowed interim compensation and reimbursement of expenses in the amount of \$2,007,046.10 for the period set forth in the Application.

2. The Debtors are authorized to disburse any unpaid amounts allowed by paragraph 1 of this Order.

Signed: February 06, 2024

  
\_\_\_\_\_  
Christopher Lopez  
United States Bankruptcy Judge

<sup>1</sup> The Debtor entities in these chapter 11 cases, along with the last four digits of each Debtor entity's federal tax identification number, are: Sorrento Therapeutics, Inc. (4842) and Scintilla Pharmaceuticals, Inc. (7956). The Debtors' service address is: 9380 Judicial Drive, San Diego, CA 92121.